Literature DB >> 22476802

[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences].

J Rohayem1, S Kliesch.   

Abstract

Androgen deprivation therapy (ADT) is effective in prolonging the progression free survival of patients with symptomatic/metastatic prostate cancer (PC). The reduction of clinical symptoms of tumour disease and the reduction of tumour growth and metastatic dissemination is accompanied by systemic consequences of testosterone deficiency. These are hot flushes, fatigue due to reduction of muscular strength and muscle mass as well as anaemia. Moreover, patients develop cognitive impairment und depressive mood. Weight gain with insulin resistance, disturbances of lipid metabolism and gynecomastia are other effects of androgen deficiency. A decrease in bone mineral density may lead to an increased susceptibility to bone fractures. There are several options to reduce these side effects of ADT, e.g. physical activity, dietary supplementation, tailored pharmacological therapy and psychotherapy. The knowledge of these adjuvant treatment options, despite their palliative character, is relevant to optimize the quality of life of these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476802     DOI: 10.1007/s00120-012-2808-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  24 in total

1.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

2.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

3.  Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.

Authors:  Johan F Langenhuijsen; Dirk Badhauser; Berthold Schaaf; Lambertus A L M Kiemeney; J Alfred Witjes; Peter F A Mulders
Journal:  Urol Oncol       Date:  2011-05-10       Impact factor: 3.498

4.  Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.

Authors:  M Moguilewsky; J Fiet; C Tournemine; J P Raynaud
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

5.  Fracture risk in men with prostate cancer: a population-based study.

Authors:  L Joseph Melton; Michael M Lieber; Elizabeth J Atkinson; Sara J Achenbach; Horst Zincke; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

6.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Authors:  Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai
Journal:  Circulation       Date:  2010-02-01       Impact factor: 29.690

Review 7.  Managing hot flushes in men after prostate cancer--a systematic review.

Authors:  Jessica Frisk
Journal:  Maturitas       Date:  2009-12-04       Impact factor: 4.342

8.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors:  Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.

Authors:  Patrick E Teloken; Michael Ohebshalom; Najeeb Mohideen; John P Mulhall
Journal:  J Urol       Date:  2007-10-15       Impact factor: 7.450

View more
  1 in total

1.  [Antihormonal therapy in prostate cancer : Side effects].

Authors:  C H Ohlmann; P Thelen
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.